Ocean Biomedical, Inc. (OCEA): Nasdaq/NYSE listing notice — Ocean Biomedical notified by Nasdaq of MVLS below $35M minimum; 180 days to regain compliance

Ocean Biomedical, Inc.

Nasdaq notified Ocean Biomedical on Jan 17, 2024 that its MVLS was below $35M minimum for 30 consecutive business days.
Company has until July 15, 2024 to regain compliance; MVLS must close at $35M+ for 10 consecutive business days.
If not compliant by July 15, Nasdaq may delist; company can appeal to a Hearings Panel.
No immediate effect on trading; stock continues trading under symbol OCEA.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Ocean Biomedical, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2), 5810(c)(3)(C)

Exact text from the filing

January 17, 2024, Ocean Biomedical, Inc. (the “ Company ”) was notified (the “ Notification Letter ”) by The Nasdaq Stock Market, LLC (“ Nasdaq ”) that for the last thirty (30) consecutive business days, the Company’s Market Value of Listed Securities (“ MVLS ”) has been below the minimum requirement of $35 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on the Nasdaq Capital Market under the symbol

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ocean Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-003091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.